Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8) is a naturally occurring human fusion transcript formed by transcriptional read-through between the neighboring PRR5 and ARHGAP8 genes[4][1]. The resulting fusion protein contains sequence elements from both parental gene products, including domains typical of RhoGAP proteins. The biological function of PRR5-ARHGAP8 itself has not been determined experimentally; however, PRR5 is a subunit of the mTORC2 kinase complex involved in neuronal survival, energy regulation, and proliferation, while ARHGAP8 is a GAP family protein regulating cytoskeletal dynamics and Rho GTPase signaling[1][2][4]. Expression of this fusion protein occurs at low levels and appears tissue-specific. Genome-wide association studies suggest a possible link to binge eating behavior in the context of bipolar disorder, but no direct therapeutic, biomarker, or disease-modifying roles have been confirmed for the fusion at present[1][4].
None established for direct targeted inhibition or activation—mechanism unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8).